BR102012000721B8 - Processo para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário de etoricoxib , uso de um catalisador de paládio e uso de um ligante xantphos - Google Patents

Processo para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário de etoricoxib , uso de um catalisador de paládio e uso de um ligante xantphos

Info

Publication number
BR102012000721B8
BR102012000721B8 BR102012000721A BR102012000721A BR102012000721B8 BR 102012000721 B8 BR102012000721 B8 BR 102012000721B8 BR 102012000721 A BR102012000721 A BR 102012000721A BR 102012000721 A BR102012000721 A BR 102012000721A BR 102012000721 B8 BR102012000721 B8 BR 102012000721B8
Authority
BR
Brazil
Prior art keywords
methylpyridin
ethanone
methylsulfonyl
phenyl
preparing
Prior art date
Application number
BR102012000721A
Other languages
English (en)
Other versions
BR102012000721A2 (pt
BR102012000721B1 (pt
Inventor
Andrea Caporale
Andrea Castellin
Francesco Fontana
De Lucchi Ottorino
Paolo Stabile
Stefano Tartaggia
Original Assignee
Fis Fabbrica Italiana Sintetici Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fis Fabbrica Italiana Sintetici Spa filed Critical Fis Fabbrica Italiana Sintetici Spa
Publication of BR102012000721A2 publication Critical patent/BR102012000721A2/pt
Publication of BR102012000721B1 publication Critical patent/BR102012000721B1/pt
Publication of BR102012000721B8 publication Critical patent/BR102012000721B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyridine Compounds (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

processo melhorado para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário de etoricoxib. a presente invenção refere-se a um processo para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário da síntese de etoricoxib. a síntese dos intermediários úteis para tal preparação também é descrita.
BR102012000721A 2011-03-09 2012-01-11 Processo para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário de etoricoxib , uso de um catalisador de paládio e uso de um ligante xantphos BR102012000721B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2011A000362 2011-03-09
IT000362A ITMI20110362A1 (it) 2011-03-09 2011-03-09 Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
IT000647A ITMI20110647A1 (it) 2011-03-09 2011-04-15 Procedimento migliorato per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
ITMI2011A000647 2011-04-15

Publications (3)

Publication Number Publication Date
BR102012000721A2 BR102012000721A2 (pt) 2013-07-23
BR102012000721B1 BR102012000721B1 (pt) 2021-09-28
BR102012000721B8 true BR102012000721B8 (pt) 2022-01-04

Family

ID=43977032

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102012000721A BR102012000721B8 (pt) 2011-03-09 2012-01-11 Processo para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário de etoricoxib , uso de um catalisador de paládio e uso de um ligante xantphos

Country Status (8)

Country Link
US (1) US8664402B2 (pt)
EP (1) EP2497767B1 (pt)
JP (1) JP6067228B2 (pt)
CN (1) CN102731374B (pt)
BR (1) BR102012000721B8 (pt)
ES (1) ES2424250T3 (pt)
IT (2) ITMI20110362A1 (pt)
MX (1) MX2012000569A (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
ITMI20121947A1 (it) * 2012-11-15 2014-05-16 Erregierre Spa Processo di sintesi di un intermedio nella produzione di etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
CN103664754B (zh) * 2013-11-08 2016-05-25 上海交通大学 制备1-(6-甲基吡啶-3-基)-2-[4-甲硫基-苯基]乙酮的方法
WO2015198850A1 (ja) * 2014-06-26 2015-12-30 住友化学株式会社 フェノール化合物の製造方法
CN104045596B (zh) * 2014-06-27 2017-03-22 成都克莱蒙医药科技有限公司 制备依托考昔中间体1‑(6‑甲基吡啶‑3‑基)‑2‑[4‑(甲磺酰基)苯基]乙酮的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR015938A1 (es) 1997-09-25 2001-05-30 Merck Sharp & Dohme Procedimiento para preparar diaril piridinas utiles como inhibidores cox-2 y compuesto intermediario
ATE272613T1 (de) 1998-04-24 2004-08-15 Merck & Co Inc Verfahren zur synthese von cox-2 inhibitoren
US6072073A (en) * 1998-08-21 2000-06-06 Yale University Carbonyl arylations and vinylations using transition metal catalysts
WO2001007410A1 (en) 1999-07-27 2001-02-01 Lonza Ag Process for preparing 1-(6-methylpyridin-3-yl)-2-[(4-(methylsulphonyl) phenyl] ethanone
IT1315243B1 (it) * 1999-10-15 2003-02-03 Zambon Spa Processo di ossidazione per la preparazione di intermedi utili nellasintesi di diarilpiridine
JP2005501822A (ja) * 2001-06-27 2005-01-20 メルク フロスト カナダ アンド カンパニー 置換８−アリールキノリン系ｐｄｅ４阻害薬
EP2270006A1 (en) * 2002-08-08 2011-01-05 Amgen, Inc Pyridazine derivatives useful as vanilloid receptor ligands
TWI432446B (zh) * 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TW200841879A (en) * 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same

Also Published As

Publication number Publication date
US20120232281A1 (en) 2012-09-13
BR102012000721A2 (pt) 2013-07-23
ITMI20110647A1 (it) 2012-09-10
CN102731374B (zh) 2015-05-06
ES2424250T3 (es) 2013-09-30
MX2012000569A (es) 2012-09-10
EP2497767B1 (en) 2013-05-29
BR102012000721B1 (pt) 2021-09-28
CN102731374A (zh) 2012-10-17
JP2012188414A (ja) 2012-10-04
US8664402B2 (en) 2014-03-04
EP2497767A1 (en) 2012-09-12
JP6067228B2 (ja) 2017-01-25
ITMI20110362A1 (it) 2012-09-10

Similar Documents

Publication Publication Date Title
CO7160104A2 (es) Inhibidores de virus de hepatitis c
BR102012000721B8 (pt) Processo para preparar 1-(6-metilpiridin-3-il)-2-[4-(metilsulfonil)fenil]etanona, um intermediário de etoricoxib , uso de um catalisador de paládio e uso de um ligante xantphos
CR11802A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
ECSP12011581A (es) Inhibidores de bace
CR11776A (es) Inhibidores de bace
DK2618803T3 (da) Vandig kosmetisk sammensætning, der omfatter alkylcellulose
CY1123456T1 (el) Μεθοδος παρασκευης οπτικως καθαρων και προαιρετικως υποκατεστημενων παραγωγων 2-(1-υδροξυ-αλκυλ)-χρωμεν-4-ονης και χρηση αυτων στην παρασκευη φαρμακευτικων ουσιων
BR112014014452A2 (pt) derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos
CR20140275A (es) Triazolopiridinas sustituidas
BR112013031493A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto.
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
CR20140554A (es) Compuestos de acido dimetil-benzoico
BR112013031405A2 (pt) piridopirazinas substituídas como novos inibidores de syk
TN2015000261A1 (fr) Dérivés d'imidazopyridazine servant de modulateurs des recepteurs gabaa
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
CR20140553A (es) Compuestos de fenoxietil piperidina
CL2014003059A1 (es) Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose.
UA113638C2 (xx) 4-(бензоімідазол-2-іл)-тіазольні сполуки та споріднені азапохідні
CL2013002581A1 (es) Compuestos derivados de indol-y -bencimidazol carboxamidas; pprocedimiento para prepararlos; uso de dichos còmpuestos para producir plaguicidas; y compuestos intermediarios.
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
UY32755A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparación y su utilización farmacéutica como inhibidores de fosforilación de akt (pkb).
EA201400475A1 (ru) Способы получения новых производных бензимидазола
BR112015007823A2 (pt) derivados de ácido hialurônico modificado e uso dos mesmos
BR112013023575A8 (pt) novo derivado de octaidrotienoquinolina, composição farmacêutica compreendendo derivado, e uso destes
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVACA AO DOS TERMOS DO

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA A?O DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVACA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06V Preliminary requirement: patent application procedure suspended [chapter 6.22 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/01/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2647 DE 28/09/2021 QUANTO AO INVENTOR